Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012

Description: Examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012. Key factors discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified to buffer the decline include the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance. The report also evaluates the emerging market sector of cognitive and memory impairment and shows the extent of R&D activities within the field. Analysis of both sectors reveals candidates that have top-line earning prospects and also provides an insight into potential licensing or acquisition opportunities in promising psychopharmacotherapy market subsectors.

Objectives of the Report

The objectives of this report are to provide a detailed analysis of the global psychopharmacotherapeutic market related to mood disorders and cognitive impairment. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Research Methodology

The contents of this report are derived from in-depth research-based surveys of the industry and proprietary analytical assessment tools. Source material also comprises the following:

- Company information
- Personal communication
- Trade press articles
- News releases
- Internet-based research
- Library research
- Scientific periodicals
- Product information
- Market analyst data
- Public information datasets
- Conference proceedings
- Medical/pharma associations

REPORT HIGHLIGHTS AND KEY FINDINGS

- Pharmacotherapies indicated for mood disorders account for a market valued at US$17.4 billion, which is forecast to decrease 13.6% CAGR to US$15 billion by 2012
- Critical analysis of depression, anxiety disorders, and cognitive and memory impairment
- Review of epidemiological, aetiological, and therapeutic data for key therapy areas
- Analysis of 10 marketed products and inclusion of 88 R&D candidates identified in preclinical to clinical stages of development for depressive illnesses and cognitive impairment
- Sales estimates (US$) to 2012 for major therapy areas
- Strategic insights for life-cycle optimization and product development
- Critical evaluation of leading antidepressants
- Emerging markets identified and sector analysis
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by therapy area
- Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
- High revenue-yielding prospects identified with projected sales estimations
- R&D pipeline positioning for key therapy areas
WHAT CAN I LEARN FROM THIS REPORT?
- Which antidepressants are the current and potential future market leaders
- Insight into the main psychopharmacotherapies for depression and anxiety disorders
- How companies optimize product life cycle through supplementary indications and reformulation
- Which premarket antidepressants are identified as potential blockbusters
- Which companies are developing drugs for cognitive impairment and memory deficits
- Sales predictions to 2012 for leading antidepressants/anxiolytics
- What the likely impact of pipeline products will be on value growth over the next decade
- Which generic defence strategies are being employed by research-based companies
- How generic companies are becoming increasingly litigious in advance of patent expiry
- Which therapy subsectors could be niche market opportunities for depressive illnesses
- What the future outlook could be for marketed antidepressants and anxiolytics
- Insight into R&D trends for antidepressants, and drugs for cognitive impairment
- Which molecules and compounds are main R&D clusters
- What are the top prospects for mood disorders, cognitive impairment, and memory deficits over the next decade and to 2020?
Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered...

Contents:
List of Tables
List of Figures
Executive Summary
Objectives of the Report
Research Methodology

Chapter 1 Introduction to Mood Disorders and Cognitive Impairment
Depression
Prevalence
Aetiology of Depression
Types of Depression
Major depression
Dysthymia
Bipolar Disorder
Symptoms of Depression
Anxiety Disorders
Prevalence
Cognitive Impairments and Memory Deficits
Prevalence
Pharmacotherapy for Cognitive Impairment

Chapter 2 The Global Market for Mood Disorders: Depression and Anxiety
Mood Disorders: Depression and Anxiety
Market Overview of Drugs to Treat Depression and Anxiety Disorders
Market Analysis and Insights for Drugs to Treat Depressive Illnesses
Market Analysis: Antidepressant Therapy Area
Prozac (Fluoxetine) - Eli Lilly
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cymbalta (Duloxetine) - Eli Lilly/Boehringer Ingelheim
Product Overview
Indications and Supplementary Labelling
Sales Prospects
Commercial Outlook
Zoloft/Lustral (Sertraline) - Pfizer
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Seroxat/Paxil/Deroxat (Paroxetine) - GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Wellbutrin (Bupropion) - GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Effexor (Venlafaxine) - Wyeth
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Remeron/Zispin (Mirtazapine) - Organon/Akzo Nobel
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipramil/Celexa (Citalopram) - Lundbeck/Forest Laboratories
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipralex/Lexapro (Escitalopram) - Lundbeck/Forest
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Future Considerations and Market Insights for the Antidepressant Market
Pipeline Antidepressants
Pipeline Focus
Valdoxan (Agomelatine) - Servier
Pharmacotherapeutics for Cognitive Impairment and /Memory Deficits
Future Market Focus - Age-Related Cognitive Decline
Nootropil (Piracetam) - UCB Pharma
Companies Developing Drugs for Cognitive and Memory Impairment
Egb 761/Tanakan - Ipsen

Chapter 3 Drugs in Research and Development
Pipeline Mood Stabilizers and Drugs for Cognitive Impairment
Drugs in Development for Mood Disorders: Antidepressants and Anxiolytics
Depression and Anxiety: Research and Development Overview
Drugs in Development for Cognitive and Memory Impairment
Cognitive/Memory Impairment - Research and Development Overview

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
Data Analysis, Therapy Forecasting, and Prospect Mining
Market Analysis and Therapy Forecasting
Antidepressants and Anxiolytics
Therapy Area Forecasts
Comparative Analysis: Antidepressant/Anxiolytic Product Sales
Prospect Mining
Mood Disorders: Depression and Anxiety
Cognitive and Memory Impairment
Therapy Area Forecasts, 2012 and 2020

Chapter 5 Report Synopsis
Depressive/Anxiety and Cognitive/Memory Impairment - Key Data Points

Bibliography and Reference Sources

List of Tables
Table 1.1 Role of Neurotransmitters in Depression
Table 1.2 Symptoms of Depression and Bipolar Disorder/Mania
Table 1.3 Major Anxiety Disorders
Table 1.4 Causes of Dementia
Table 2.1 Estimated Global Sales & Forecasts of Leading Antidepressants, 2004-2012 (US$m)
Table 2.2 Estimated Annual Growth Rates of Leading Antidepressants (%), 2004-2012
Table 2.3 Leading Antidepressants Ranked by Sales, 2005 & 2012
Table 2.4 Primary and Secondary Indications for Antidepressants
Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Prozac, 2005-2012
Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Cymbalta, 2005-2012
Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Zoloft, 2005-2012
Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Seroxat/Paxil, 2005-2012
Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Wellbutrin, 2005-2012
Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Effexor, 2005-2012
Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Remeron, 2005-2012
Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Cipramil/Celexa, 2005-12
Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Cipralex/Lexapro, 2005-12
Table 2.14 Drugs in Development for Cognitive and Memory Impairment, 2005 (partial)
Table 3.1 Drugs in Development for Depression and Anxiety, 2005
Table 3.2 Drugs in Development for Cognitive and Memory Impairment, 2005
Table 4.1 Global Drug Market for Antidepressants and Anxiolytics (US$m) 2004-2012
Table 4.2 Therapy Area Forecasts for the Global Mood Disorders and Cognitive Impairment Market Sectors, 2012 and 2020

List of Figures
Figure 2.1 Estimated Global Sales of Leading Antidepressants, 2005 & 2012
Figure 2.2 Estimated Market Share of Leading Antidepressants, 2005 & 2012
Figure 4.1 Therapy Area Forecasts for Antidepressants and Anxiolytics, 2005 & 2012 (US$m)
Figure 4.2 Comparative Analysis of Leading Antidepressants and Anxiolytics 2004-2012
Figure 4.3 Key Antidepressant/Anxiolytic Prospects in the CNS Development Pipeline, 2005
Figure 4.4 Key Cognitive and Memory Impairment Prospects in the CNS Development Pipeline, 2005

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/310984/](http://www.researchandmarkets.com/reports/310984/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012
Web Address: http://www.researchandmarkets.com/reports/310984/
Office Code: SCD2SIBC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>Single User:</td>
<td>USD 1065</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td></td>
<td>USD 1105 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>Enterprisewide:</td>
<td>USD 6163</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________________________ Last Name: ______________________________
Email Address: * ______________________________________
Job Title: ____________________________________________
Organisation: _________________________________________
Address: _____________________________________________
City: _________________________________________________
Postal / Zip Code: ____________________________________
Country: _____________________________________________
Phone Number: ________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:  Please transfer funds to:
Account number  833 130 83
Sort code  98-53-30
Swift code  ULSBIE2D
IBAN number  IE78ULSB98533083313083
Bank Address  Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:  

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World